APUS — Apimeds Pharmaceuticals US, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1894525 ·
Last close
$5.02
Market Cap
$7.58M
52W High
$59.70
52W Low
$1.51
ADV30
7,716,534
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,278,760 | -20,173,129 | 127,623,697 | 278,371 | 21,175,156 |
| Mar 2026 | 0 | — | -12,185,694 | -35,059,852 | 141,219,157 | 979,534 | 14,703,698 |
| Dec 2025 | 0 | — | -7,040,051 | -1,155,292 | 164,183,736 | 1,636,655 | 10,835,909 |
| Sep 2025 | 0 | — | -1,844,239 | -1,781,255 | 9,250,036 | 6,986,617 | 1,089,384 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,973,191
Investing CF
$-9,569,745
Financing CF
$21,272,127
CapEx
$-53,358
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-26.95
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-45,452,913
Inventory
—
Receivables
—
ST Investments
$1,500,000
EBIT TTM
$-39,554,208
Pretax Income TTM
$-40,658,592
Interest Exp TTM
$1,104,384
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,912,562 | -6,001,137 | 164,183,736 | 10,835,909 | 153,347,827 | -8,925,777 |
| Dec 2024 | 0 | -1,275,095 | -1,389,990 | 13,057 | 1,371,178 | -1,358,121 | -733,526 |
| Dec 2023 | 0 | -747,436 | -777,694 | 422,076 | 390,207 | 31,869 | -627,790 |
| Dec 2022 | 0 | -639,529 | -668,666 | 6,171 | 719,777 | -713,606 | -448,167 |
TTM Snapshot
Revenues TTM
$107,599
NetIncome TTM
$-40,658,592
OpCashFlow TTM
—
Assets (Latest)
$141,219,157
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LGVN | Longeveron Inc. | $7.55M | $2.48 | — |
| APRE | Aprea Therapeutics, Inc. | $7.61M | $0.60 | — |
| FBLG | FibroBiologics, Inc. | $7.52M | $1.13 | — |
| SKYE | Skye Bioscience, Inc. | $7.48M | $1.69 | — |
| INM | InMed Pharmaceuticals Inc. | $7.47M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
Why Is Apimeds Pharmaceuticals Stock Gaining Monday?
2026-10-05 14:08 · Yahoo
Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon
2026-07-08 01:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.